Inflammation:治療薬開発パイプライン動向(2014年上半期、グローバル製薬市場)

◆英語タイトル:Inflammation - Pipeline Review, H1 2014
◆商品コード:GMDHC5069IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年6月30日
◆ページ数:1103
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥780,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Inflammation – Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Inflammation – Pipeline Review, H1 2014’, provides an overview of the Inflammation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Inflammation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Inflammation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Inflammation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Inflammation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 11
Inflammation Overview 12
Therapeutics Development 13
Inflammation – Therapeutics under Development by Companies 15
Inflammation – Therapeutics under Investigation by Universities/Institutes 35
Inflammation – Pipeline Products Glance 41
Inflammation – Products under Development by Companies 45
Inflammation – Products under Investigation by Universities/Institutes 75
Inflammation – Companies Involved in Therapeutics Development 82
Inflammation – Therapeutics Assessment 304
Drug Profiles 333
Inflammation – Recent Pipeline Updates 959
Inflammation – Dormant Projects 1002
Inflammation – Discontinued Products 1033
Inflammation – Product Development Milestones 1036
Appendix 1043

List of Tables
Number of Products under Development for Inflammation, H1 2014 72
Number of Products under Development for Inflammation - Comparative Analysis, H1 2014 73
Number of Products under Development by Companies, H1 2014 75
Number of Products under Development by Companies, H1 2014 (Contd..1) 76
Number of Products under Development by Companies, H1 2014 (Contd..2) 77
Number of Products under Development by Companies, H1 2014 (Contd..3) 78
Number of Products under Development by Companies, H1 2014 (Contd..4) 79
Number of Products under Development by Companies, H1 2014 (Contd..5) 80
Number of Products under Development by Companies, H1 2014 (Contd..6) 81
Number of Products under Development by Companies, H1 2014 (Contd..7) 82
Number of Products under Development by Companies, H1 2014 (Contd..8) 83
Number of Products under Development by Companies, H1 2014 (Contd..9) 84
Number of Products under Development by Companies, H1 2014 (Contd..10) 85
Number of Products under Development by Companies, H1 2014 (Contd..11) 86
Number of Products under Development by Companies, H1 2014 (Contd..12) 87
Number of Products under Development by Companies, H1 2014 (Contd..13) 88
Number of Products under Development by Companies, H1 2014 (Contd..14) 89
Number of Products under Development by Companies, H1 2014 (Contd..15) 90
Number of Products under Development by Companies, H1 2014 (Contd..16) 91
Number of Products under Development by Companies, H1 2014 (Contd..17) 92
Number of Products under Development by Companies, H1 2014 (Contd..18) 93
Number of Products under Investigation by Universities/Institutes, H1 2014 95
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 96
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 97
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 98
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 99
Comparative Analysis by Late Stage Development, H1 2014 100
Comparative Analysis by Clinical Stage Development, H1 2014 101
Comparative Analysis by Early Stage Development, H1 2014 102
Comparative Analysis by Unknown Stage Development, H1 2014 103
Products under Development by Companies, H1 2014 104
Products under Development by Companies, H1 2014 (Contd..1) 105
Products under Development by Companies, H1 2014 (Contd..2) 106
Products under Development by Companies, H1 2014 (Contd..3) 107
Products under Development by Companies, H1 2014 (Contd..4) 108
Products under Development by Companies, H1 2014 (Contd..5) 109
Products under Development by Companies, H1 2014 (Contd..6) 110
Products under Development by Companies, H1 2014 (Contd..7) 111
Products under Development by Companies, H1 2014 (Contd..8) 112
Products under Development by Companies, H1 2014 (Contd..9) 113
Products under Development by Companies, H1 2014 (Contd..10) 114
Products under Development by Companies, H1 2014 (Contd..11) 115
Products under Development by Companies, H1 2014 (Contd..12) 116
Products under Development by Companies, H1 2014 (Contd..13) 117
Products under Development by Companies, H1 2014 (Contd..14) 118
Products under Development by Companies, H1 2014 (Contd..15) 119
Products under Development by Companies, H1 2014 (Contd..16) 120
Products under Development by Companies, H1 2014 (Contd..17) 121
Products under Development by Companies, H1 2014 (Contd..18) 122
Products under Development by Companies, H1 2014 (Contd..19) 123
Products under Development by Companies, H1 2014 (Contd..20) 124
Products under Development by Companies, H1 2014 (Contd..21) 125
Products under Development by Companies, H1 2014 (Contd..22) 126
Products under Development by Companies, H1 2014 (Contd..23) 127
Products under Development by Companies, H1 2014 (Contd..24) 128
Products under Development by Companies, H1 2014 (Contd..25) 129
Products under Development by Companies, H1 2014 (Contd..26) 130
Products under Development by Companies, H1 2014 (Contd..27) 131
Products under Development by Companies, H1 2014 (Contd..28) 132
Products under Development by Companies, H1 2014 (Contd..29) 133
Products under Investigation by Universities/Institutes, H1 2014 134
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 135
Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 136
Products under Investigation by Universities/Institutes, H1 2014 (Contd..3) 137
Products under Investigation by Universities/Institutes, H1 2014 (Contd..4) 138
Products under Investigation by Universities/Institutes, H1 2014 (Contd..5) 139
Products under Investigation by Universities/Institutes, H1 2014 (Contd..6) 140
Inflammation - Pipeline by Bristol-Myers Squibb Company, H1 2014 141
Inflammation - Pipeline by Johnson & Johnson, H1 2014 142
Inflammation - Pipeline by Boehringer Ingelheim GmbH, H1 2014 143
Inflammation - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 144
Inflammation - Pipeline by Amgen Inc., H1 2014 145
Inflammation - Pipeline by Questcor Pharmaceuticals, Inc., H1 2014 146
Inflammation - Pipeline by GlaxoSmithKline plc, H1 2014 147
Inflammation - Pipeline by Genentech, Inc., H1 2014 148
Inflammation - Pipeline by Nektar Therapeutics, H1 2014 149
Inflammation - Pipeline by Agenus, Inc., H1 2014 150
Inflammation - Pipeline by MedImmune, LLC, H1 2014 151
Inflammation - Pipeline by Gilead Sciences, Inc., H1 2014 152
Inflammation - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 153
Inflammation - Pipeline by Merck & Co., Inc., H1 2014 154
Inflammation - Pipeline by Ablynx NV, H1 2014 155
Inflammation - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 156
Inflammation - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2014 157
Inflammation - Pipeline by Euroscreen S.A., H1 2014 158
Inflammation - Pipeline by Novo Nordisk A/S, H1 2014 159
Inflammation - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 160
Inflammation - Pipeline by Reliance Life Sciences Pvt. Ltd., H1 2014 161
Inflammation - Pipeline by Piramal Enterprises Limited, H1 2014 162
Inflammation - Pipeline by Amorepacific Corporation, H1 2014 163
Inflammation - Pipeline by Astellas Pharma Inc., H1 2014 164
Inflammation - Pipeline by Kowa Company, Ltd., H1 2014 165
Inflammation - Pipeline by LEO Pharma A/S, H1 2014 166
Inflammation - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2014 167
Inflammation - Pipeline by Pfizer Inc., H1 2014 168
Inflammation - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 169
Inflammation - Pipeline by UCB S.A., H1 2014 170
Inflammation - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 171
Inflammation - Pipeline by Exelixis, Inc., H1 2014 172
Inflammation - Pipeline by Celgene Corporation, H1 2014 173
Inflammation - Pipeline by Bayer AG, H1 2014 174
Inflammation - Pipeline by Incyte Corporation, H1 2014 175
Inflammation - Pipeline by Merck KGaA, H1 2014 176
Inflammation - Pipeline by Evotec AG, H1 2014 177
Inflammation - Pipeline by Harbor Therapeutics, Inc., H1 2014 178
Inflammation - Pipeline by Momenta Pharmaceuticals, Inc., H1 2014 179
Inflammation - Pipeline by Star Scientific, Inc., H1 2014 180
Inflammation - Pipeline by Genfit SA, H1 2014 181
Inflammation - Pipeline by Can-Fite BioPharma Ltd., H1 2014 182
Inflammation - Pipeline by Karo Bio AB, H1 2014 183
Inflammation - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 184
Inflammation - Pipeline by TG Therapeutics, Inc., H1 2014 185
Inflammation - Pipeline by Lpath, Inc., H1 2014 186
Inflammation - Pipeline by Lupin Limited, H1 2014 187
Inflammation - Pipeline by Basilea Pharmaceutica AG, H1 2014 188
Inflammation - Pipeline by NicOx S.A., H1 2014 189
Inflammation - Pipeline by Compugen Ltd., H1 2014 190
Inflammation - Pipeline by Orchid Chemicals & Pharmaceuticals Ltd, H1 2014 191
Inflammation - Pipeline by Palatin Technologies, Inc., H1 2014 192
Inflammation - Pipeline by Pharmaxis Limited, H1 2014 193
Inflammation - Pipeline by Alexion Pharmaceuticals, Inc., H1 2014 194
Inflammation - Pipeline by Portola Pharmaceuticals, Inc., H1 2014 195
Inflammation - Pipeline by CSL Limited, H1 2014 196
Inflammation - Pipeline by Cytomedix, Inc., H1 2014 197
Inflammation - Pipeline by Array BioPharma Inc., H1 2014 198
Inflammation - Pipeline by Dynavax Technologies Corporation, H1 2014 199
Inflammation - Pipeline by XOMA Corporation, H1 2014 200
Inflammation - Pipeline by MorphoSys AG, H1 2014 201
Inflammation - Pipeline by BioInvent International AB, H1 2014 202
Inflammation - Pipeline by Transgene SA, H1 2014 203
Inflammation - Pipeline by Progen Pharmaceuticals Limited, H1 2014 204
Inflammation - Pipeline by JW Pharmaceutical Corporation, H1 2014 205
Inflammation - Pipeline by Galectin Therapeutics, Inc., H1 2014 206
Inflammation - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2014 207
Inflammation - Pipeline by Biotie Therapies Corp., H1 2014 208
Inflammation - Pipeline by LTT Bio-Pharma Co., Ltd., H1 2014 209
Inflammation - Pipeline by Galapagos NV, H1 2014 210
Inflammation - Pipeline by Synta Pharmaceuticals Corp., H1 2014 211
Inflammation - Pipeline by BioAlliance Pharma SA, H1 2014 212
Inflammation - Pipeline by Innate Pharma SA, H1 2014 213
Inflammation - Pipeline by MetrioPharm AG, H1 2014 214
Inflammation - Pipeline by Proteo, Inc., H1 2014 215
Inflammation - Pipeline by Verona Pharma Plc, H1 2014 216
Inflammation - Pipeline by Angelini Group, H1 2014 217
Inflammation - Pipeline by Affitech A/S, H1 2014 218
Inflammation - Pipeline by Debiopharm International S.A., H1 2014 219
Inflammation - Pipeline by Chroma Therapeutics Ltd., H1 2014 220
Inflammation - Pipeline by Advinus Therapeutics Ltd., H1 2014 221
Inflammation - Pipeline by CJ CheilJedang Corp., H1 2014 222
Inflammation - Pipeline by Antitope Ltd., H1 2014 223
Inflammation - Pipeline by Axxam SpA, H1 2014 224
Inflammation - Pipeline by INSYS Therapeutics, Inc., H1 2014 225
Inflammation - Pipeline by Aurigene Discovery Technologies Limited, H1 2014 226
Inflammation - Pipeline by Alba Therapeutics Corporation, H1 2014 227
Inflammation - Pipeline by AcurePharma AB, H1 2014 228
Inflammation - Pipeline by Ambit Biosciences Corporation, H1 2014 229
Inflammation - Pipeline by Viron Therapeutics, Inc., H1 2014 230
Inflammation - Pipeline by Immupharma Plc, H1 2014 231
Inflammation - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 232
Inflammation - Pipeline by Molecular Partners AG, H1 2014 233
Inflammation - Pipeline by Physica Pharma, H1 2014 234
Inflammation - Pipeline by Acceleron Pharma, Inc., H1 2014 235
Inflammation - Pipeline by Lipicard Technologies Limited, H1 2014 236
Inflammation - Pipeline by Conaris Research Institute AG, H1 2014 237
Inflammation - Pipeline by Hutchison MediPharma Limited, H1 2014 238
Inflammation - Pipeline by Affibody AB, H1 2014 239
Inflammation - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2014 240
Inflammation - Pipeline by Aquinox Pharmaceuticals Inc., H1 2014 241
Inflammation - Pipeline by Argos Therapeutics, Inc., H1 2014 242
Inflammation - Pipeline by Aegera Therapeutics Inc., H1 2014 243
Inflammation - Pipeline by Anchor Therapeutics, Inc., H1 2014 244
Inflammation - Pipeline by AnaptysBio, Inc., H1 2014 245
Inflammation - Pipeline by Allozyne, Inc., H1 2014 246
Inflammation - Pipeline by Funxional Therapeutics Ltd, H1 2014 247

List of Figures
Number of Products under Development for Inflammation, H1 2014 72
Number of Products under Development for Inflammation - Comparative Analysis, H1 2014 73
Number of Products under Development by Companies, H1 2014 74
Number of Products under Investigation by Universities/Institutes, H1 2014 94
Comparative Analysis by Clinical Stage Development, H1 2014 101
Comparative Analysis by Early Stage Products, H1 2014 102
Assessment by Monotherapy Products, H1 2014 363
Assessment by Combination Products, H1 2014 364
Number of Products by Top 10 Target, H1 2014 365
Number of Products by Stage and Top 10 Target, H1 2014 366
Number of Products by Top 10 Mechanism of Action, H1 2014 375
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 376
Number of Products by Top 10 Route of Administration, H1 2014 386
Number of Products by Stage and Top 10 Route of Administration, H1 2014 387
Number of Products by Top 10 Molecule Type, H1 2014 389
Number of Products by Stage and Top 10 Molecule Type, H1 2014 390

【掲載企業】

Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Questcor Pharmaceuticals, Inc.
GlaxoSmithKline plc
Genentech, Inc.
Nektar Therapeutics
Agenus, Inc.
MedImmune, LLC
Gilead Sciences, Inc.
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
Ablynx NV
Dainippon Sumitomo Pharma Co., Ltd.
Taisho Pharmaceutical Co., Ltd.
Euroscreen S.A.
Novo Nordisk A/S
Infinity Pharmaceuticals, Inc.
Reliance Life Sciences Pvt. Ltd.
Piramal Enterprises Limited
Amorepacific Corporation
Astellas Pharma Inc.
Kowa Company, Ltd.
LEO Pharma A/S
Mitsubishi Tanabe Pharma Corporation
Pfizer Inc.
Teva Pharmaceutical Industries Limited
UCB S.A.
Zydus Cadila Healthcare Limited
Exelixis, Inc.
Celgene Corporation
Bayer AG
Incyte Corporation
Merck KGaA
Evotec AG
Harbor Therapeutics, Inc.
Momenta Pharmaceuticals, Inc.
Star Scientific, Inc.
Genfit SA
Can-Fite BioPharma Ltd.
Karo Bio AB
Ligand Pharmaceuticals, Inc.
TG Therapeutics, Inc.
Lpath, Inc.
Lupin Limited
Basilea Pharmaceutica AG
NicOx S.A.
Compugen Ltd.
Orchid Chemicals & Pharmaceuticals Ltd
Palatin Technologies, Inc.
Pharmaxis Limited
Alexion Pharmaceuticals, Inc.
Portola Pharmaceuticals, Inc.
CSL Limited
Cytomedix, Inc.
Array BioPharma Inc.
Dynavax Technologies Corporation
XOMA Corporation
MorphoSys AG
BioInvent International AB
Transgene SA
Progen Pharmaceuticals Limited
JW Pharmaceutical Corporation
Galectin Therapeutics, Inc.
Ahn-Gook Pharmaceutical Co., Ltd.
Biotie Therapies Corp.
LTT Bio-Pharma Co., Ltd.
Galapagos NV
Synta Pharmaceuticals Corp.
BioAlliance Pharma SA
Innate Pharma SA
MetrioPharm AG
Proteo, Inc.
Verona Pharma Plc
Angelini Group
Affitech A/S
Debiopharm International S.A.
Chroma Therapeutics Ltd.
Advinus Therapeutics Ltd.
CJ CheilJedang Corp.
Antitope Ltd.
Axxam SpA
INSYS Therapeutics, Inc.
Aurigene Discovery Technologies Limited
Alba Therapeutics Corporation
AcurePharma AB
Ambit Biosciences Corporation
Viron Therapeutics, Inc.
Immupharma Plc
Upsher-Smith Laboratories, Inc.
Molecular Partners AG
Physica Pharma
Acceleron Pharma, Inc.
Lipicard Technologies Limited
Conaris Research Institute AG
Hutchison MediPharma Limited
Affibody AB
Ache Laboratorios Farmaceuticos S/A
Aquinox Pharmaceuticals Inc.
Argos Therapeutics, Inc.
Aegera Therapeutics Inc.
Anchor Therapeutics, Inc.
AnaptysBio, Inc.
Allozyne, Inc.
Funxional Therapeutics Ltd
Oxagen Limited
CompleGen, Inc.
Catabasis Pharmaceuticals, Inc.
Ambrx, Inc.
PLx Pharma Inc.
Five Prime Therapeutics, Inc.
Vaccinex, Inc.
ProNAi Therapeutics, Inc.
Vascular Biogenics Ltd.
AIM Therapeutics Inc.
NovImmune SA
TxCell SA
Endocyte, Inc.
Selexys Pharmaceuticals Corporation
CG Pharmaceuticals, Inc.
Siena Biotech S.p.A.
Polyphor Ltd.
Noxxon Pharma AG
Atox Bio Inc.
Rimonyx Pharmaceuticals Ltd.
Karus Therapeutics Limited
Omeros Corporation
Sosei Co. Ltd.
Bridge Bioresearch Plc
Enceladus Pharmaceuticals BV
Targacept, Inc.
ChemoCentryx, Inc.
Tobira Therapeutics, Inc.
Vitae Pharmaceuticals, Inc.
Resolvyx Pharmaceuticals, Inc
arGEN-X BV
Kyorin Pharmaceutical Co., Ltd.
Nuevolution A/S
Laboratorios LETI S.L.
GlycoMimetics, Inc.
Lipopharma Therapeutics SL
Vicus Therapeutics, LLC
Medisyn Technologies, Inc.
Ensemble Discovery Corporation
Medestea Research & Production S.p.A.
Encore Therapeutics Inc.
Gem Pharmaceuticals, LLC
CoDa Therapeutics, Inc.
Bial - Portela & Ca, S.A.
Adocia
Sorrento Therapeutics, Inc.
Covagen AG
Zymeworks Inc.
aTyr Pharma, Inc.
Protagonist Therapeutics Inc.
Lycera Corp.
PharmAbcine, Inc.
UNIZYME Laboratories A/S
Interprotein Corporation
Heptares Therapeutics Ltd.
Signum Biosciences, Inc.
Zyngenia, Inc.
ISU ABXIS Co.,Ltd.
Pepscan Therapeutics
Faron Pharmaceuticals Oy
SelectX Pharmaceuticals, Inc.
Sirona Biochem Corp
Cellmid Limited
Fibrocell Science, Inc.
Mirrx Therapeutics A/S
Biolab Sanus Farmaceutica Ltda.
Vichem Chemie Research Ltd.
XBiotech USA, Inc.
ImQuest Life Sciences
PharmaIN Corporation
CellAct Pharma GmbH
Serodus ASA
CytomX Therapeutics, Inc.
Celtaxsys, Inc.
InflaRx GmbH
National Pharmaceutical Corp.
TPP Global Development Ltd
Sphaera Pharma Pvt. Ltd.
APT Therapeutics, Inc.
Complix NV
Cytoguide ApS
VivaCell Biotechnology Espana S.L.
Karyopharm Therapeutics, Inc.
Apexigen, Inc.
centrose llc
Ajinomoto Pharmaceuticals Co., Ltd.
.
X-BODY BioSciences, Inc.
Lead Discovery Center GmbH
Enlivex Therapeutics Ltd
SciFluor Life Sciences, LLC
Visionary Pharmaceuticals, Inc.
Allinky Biopharma
Creabilis SA
ARA Healthcare Pvt. Ltd.
XImmune AB
Kadmon Corporation, LLC
PIQUR Therapeutics AG
Humabs BioMed SA
Istituto Italiano di Tecnologia
LondonPharma Ltd
AbbVie Inc.
Curadev Pharma Private Limited
TechnoPhage SA
ChironWells GmbH
Vipergen ApS
Pharmedartis GmbH
XL-protein GmbH
Ziarco Pharma Ltd
Netherlands Translational Research Center B.V.
Allakos Inc.
Arachos Pharma Ltd.
Thelial Technologies S.A.
MI.TO. Technology S.r.L.
Dong-A Socio Group
Iltoo Pharma
Debiopharm Group

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[Inflammation:治療薬開発パイプライン動向(2014年上半期、グローバル製薬市場)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆